ORLANDO -- Most adults with type 1 diabetes switching from an insulin pump or multiple daily injections to inhaled insulin (Afrezza) needed to increase their dose of the inhaled product to achieve ...
ORLANDO, Fla. — The inhaled insulin Afrezza combined with a long-acting basal analog offers a non-inferior insulin treatment option for people with type 1 diabetes, new phase 4 data suggest. Afrezza ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback